What is the most recent earnings date for MRTX stock?
MIRATI THERAPEUTICS INC (MRTX) last reported earnings on 11/6/2023.
NASDAQ:MRTX • US60468T1051
Past quarterly earnings results for MIRATI THERAPEUTICS INC (MRTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | -2.49 | -2.90 | 14.01% | 19.42% | 16.4M | 18.97M | -13.55% | 202.03% |
| Q2 2023 | -3.04 | -3.23 | 6.02% | 4.40% | 13.69M | 13.78M | -0.65% | 155.41% |
| Q1 2023 | -3.18 | -3.62 | 12.21% | 6.47% | 7.17M | 4.874M | 47.11% | 909.86% |
| Q4 2022 | -3.51 | -3.62 | 3.16% | 5.65% | 930K | 2.318M | -59.88% | 210.00% |
| Q3 2022 | -3.09 | -3.55 | 12.84% | -99.35% | 5.43M | 1.285M | 322.57% | -92.44% |
| Q2 2022 | -3.18 | -3.56 | 10.56% | 1.55% | 5.36M | 351.9K | 1,423.16% | - |
| Q1 2022 | -3.40 | -3.56 | 4.40% | -27.34% | 710K | 159.375K | 345.49% | - |
| Q4 2021 | -3.72 | -3.06 | -21.42% | -78.85% | 300K | 2.068M | -85.49% | -82.46% |
| Q3 2021 | -1.55 | -2.94 | 47.35% | 20.92% | 71.79M | 10.838M | 562.39% | 528.63% |
| Q2 2021 | -3.23 | -2.45 | -31.90% | -70.90% | 6.758M | -100.00% | - | |
| Q1 2021 | -2.67 | -2.18 | -22.64% | -32.18% | 141.668K | -100.00% | -100.00% | |
| Q4 2020 | -2.08 | -2.28 | 8.70% | - | 1.71M | 276.247K | 519.01% | - |
| Q3 2020 | -1.96 | -2.01 | 2.64% | - | 11.42M | 2.748M | 315.57% | - |
| Q2 2020 | -1.89 | -2.13 | 11.41% | - | 785.869K | -100.00% | - | |
| Q1 2020 | -2.02 | -1.70 | -19.06% | - | 270K | 270.3K | -0.11% | - |
Notes
MIRATI THERAPEUTICS INC (MRTX) last reported earnings on 11/6/2023.
MIRATI THERAPEUTICS INC (MRTX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, MIRATI THERAPEUTICS INC (MRTX) has beaten EPS estimates in 4 out of 4 releases.